NanoRepro AG (NNGRF) Research

NanoRepro AG specializes in the conception, production, and global distribution of swift diagnostic assays and nutritional supplements. These offerings cater to both individual consumers and healthcare professionals, operating primarily from Germany. Their diagnostic portfolio encompasses diverse health sectors, including reproductive health, general disease identification, and the detection of food sensitivities, allergic reactions, and infectious pathogens. Among their rapid diagnostic solutions are consumer-focused tests for allergies, family planning, and proactive health management. For clinical environments and medical facilities, they supply point-of-care (POC) tests designed to identify critical indicators such as HIV, cardiac Troponin I, D-dimer, streptococci antigens, influenza A/B antigens, and microalbumin. Leveraging immunochromatographic lateral flow technology, they enable the precise detection of various biomarkers, notably including rapid SARS-CoV-2 antibody and antigen tests. Furthermore, NanoRepro AG provides a range of dietary supplements specifically formulated for both men and women, which are accessible through online retail channels and pharmacies. The company's corporate headquarters are situated in Marburg, Germany.

Open NanoRepro AG (NNGRF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.